Did CV Sciences Inc (OTCMKTS:CVSI) Just Line Up a New Splash?

Did CV Sciences Inc (OTCMKTS:CVSI) Just Line Up a New Splash?

SHARE

As the CBD theme builds itself out, the market continues to embrace it in the wake of the signing of the 2018 Farm Bill, pitting companies like CV Sciences Inc (OTCMKTS:CVSI) in increasingly interesting positions. That said, there is no shortage of detractors, as the company battles both stigma and excessive momentum.

To further flesh out the story, CVSI just announced that it has engaged ICR, a leading strategic communications and advisory firm, to enhance the Company’s investor relations, media relations and corporate communications program.

CV Sciences Inc (OTCMKTS:CVSI) bills itself as a life science company, focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD).

CVSI operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors, including nutraceutical, beauty care, specialty foods, and vape.

Following the CanX Acquisition in December 2015, CV Sciences commenced its preclinical drug development program during the second quarter of 2016. The Company’s drug development efforts include pursuing synthetic-based Cannabidiol drug candidates in areas that have the potential to provide significant improvements in therapeutic patient treatments with sizable addressable markets.

The company was formerly known as CannaVEST Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.

CV Sciences Inc is led by Michael J. Mona, JR. founder of CV Sciences, Mr. Mona possesses over 30 years of senior management experience in a range of industries including real estate/construction, industrial farming, chemical processing and consumer products. Mr. Mona is a recognized industry leader in hemp farming operations and chemical extraction and has established a global supply chain of hemp-derived products.

According to company materials, “CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.”

Find out when $CVSI reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, CVSI just announced that it has engaged ICR, a leading strategic communications and advisory firm, to enhance the Company’s investor relations, media relations and corporate communications program.

The chart shows 13% tacked on to share pricing for the stock in the past month. In addition, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed 22% above its longer-run average levels.

“CV Sciences experienced significant growth in 2018 and we are well positioned to continue to accelerate our growth in 2019 and beyond as we execute our business strategy, expand our retail and e-commerce distribution, and bring innovative branded CBD products to market,” said Joseph Dowling, Chief Executive Officer.  “ICR’s capital markets and financial media expertise, combined with its significant experience in the nutritional supplement, cannabis, CPG and retail sectors will enhance our communications to all of our stakeholders, broaden exposure to institutional investors, and deepen the financial communities’ understanding of CV Sciences’ differentiated business model, growth strategy and market opportunity.  We are excited to partner with ICR as we enter this next chapter of growth for our Company and the hemp-based CBD market.”

Now commanding a market cap of $477.3M, CVSI has a significant war chest ($11M) of cash on the books, which stands against about $3M in total current liabilities. CVSI is pulling in trailing 12-month revenues of $41.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 143.3%. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $CVSI stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $CVSI, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter